152 related articles for article (PubMed ID: 37840530)
21. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Zauderer MG; Alley EW; Bendell J; Capelletto E; Bauer TM; Callies S; Szpurka AM; Kang S; Willard MD; Wacheck V; Varghese AM
Invest New Drugs; 2021 Aug; 39(4):1081-1088. PubMed ID: 33660194
[TBL] [Abstract][Full Text] [Related]
22. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
24. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
26. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
27. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols.
Narayanan G; Bilimoria MM; Hosein PJ; Su Z; Mortimer KM; Martin RCG
BMC Cancer; 2021 Jul; 21(1):785. PubMed ID: 34233640
[TBL] [Abstract][Full Text] [Related]
28. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
[TBL] [Abstract][Full Text] [Related]
29. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.
Pietrobono S; Sabbadini F; Bertolini M; Mangiameli D; De Vita V; Fazzini F; Lunardi G; Casalino S; Scarlato E; Merz V; Zecchetto C; Quinzii A; Di Conza G; Lahn M; Melisi D
Cancer Res; 2024 Jan; 84(1):118-132. PubMed ID: 37738399
[TBL] [Abstract][Full Text] [Related]
30. A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Chang C; Li X; Cheng K; Cai Z; Xiong J; Lv W; Li R; Zhang P; Cao D
Oncologist; 2023 Jul; 28(7):e575-e584. PubMed ID: 35930304
[TBL] [Abstract][Full Text] [Related]
31. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Heudel P; Frenel JS; Dalban C; Bazan F; Joly F; Arnaud A; Abdeddaim C; Chevalier-Place A; Augereau P; Pautier P; Chakiba C; You B; Lancry-Lecomte L; Garin G; Marcel V; Diaz JJ; Treilleux I; Pérol D; Fabbro M; Ray-Coquard I
JAMA Oncol; 2022 Jul; 8(7):1001-1009. PubMed ID: 35551299
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma.
Jo JH; Jung DE; Lee HS; Park SB; Chung MJ; Park JY; Bang S; Park SW; Cho S; Song SY
Int J Cancer; 2022 Nov; 151(9):1565-1577. PubMed ID: 35657348
[TBL] [Abstract][Full Text] [Related]
34. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
[TBL] [Abstract][Full Text] [Related]
35. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
[TBL] [Abstract][Full Text] [Related]
38. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T
Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154
[TBL] [Abstract][Full Text] [Related]
40. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Decker T; Marschner N; Muendlein A; Welt A; Hagen V; Rauh J; Schröder H; Jaehnig P; Potthoff K; Lerchenmüller C
Breast Cancer Res Treat; 2019 Aug; 176(3):637-647. PubMed ID: 31115844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
